Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of zelenectide pevedotin in NECTIN4-amplified advanced breast cancer
2024-517868-33-00Phase 2Authorised
- Sponsor
- Bicycle Therapeutics
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of zelenectide pevedotin in breast cancer, sponsored by Bicycle Therapeutics. Primary endpoint: Objective response rate. Planned start Jun 2025; status: authorised.
02
Drugs
zelenectide pevedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-517868-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517868-33-00.